Lexeo Therapeutics (LXEO) Other Non Operating Income (2023 - 2026)
Lexeo Therapeutics (LXEO) posted Other Non Operating Income of -$1000.0 for Q1 2026, up 99.98% sequentially from -$5.5 million in Q4 2025, and up 75.0% YoY from -$571.43 in Q1 2025.
Lexeo Therapeutics (LXEO) Other Non Operating Income (2023 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Other Non Operating Income for 4 years, with the latest figure at -$1000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 75.0% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.5 million (down 912.96% YoY) and the FY2025 annual result came in at -$5.5 million, down 914.6% from the prior year.
- Other Non Operating Income rose to -$1000.0 in Q1 2026 per LXEO's latest filing, from -$5.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $687000.0 in Q4 2024 and troughed at -$5.5 million in Q4 2025.
- A 4-year average of -$373769.2 and a median of -$4000.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income surged 9914.29% in 2024, then sank 1300.0% in 2025.
- Over 4 years, Other Non Operating Income stood at -$7000.0 in 2023, then soared by 9914.29% to $687000.0 in 2024, then plunged by 900.0% to -$5.5 million in 2025, then jumped by 99.98% to -$1000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$1000.0, -$5.5 million, and -$9000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 687,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -3,000.00 |
| Mar 31, 2023 | -4,000.00 |